Gastroenteropancreatic Neuroendocrine Tumors: Molecular Genetic Features

被引：0

作者：

Anlauf, Martin ^{[1
]}

Schmitt, Anja ^{[2
]}

Heikaus, Sebastian

Schott, Matthias ^{[3
]}

Willenberg, Holger S. ^{[3
]}

Raffel, Andreas ^{[4
]}

Krausch, Markus ^{[4
]}

Cupisti, Kenko ^{[4
]}

Stoecklein, Nikolas ^{[4
]}

Bauersfeld, Juliane ^{[5
]}

Knoefel, Wolfram T. ^{[4
]}

Komminoth, Paul ^{[5
]}

Perren, Aurel ^{[2
]}

Kloeppel, Guenter ^{[6
]}

机构：

[1] Univ Dusseldorf, Endokrines Tumorzentrum, Inst Pathol, D-40225 Dusseldorf, Germany

[2] Univ Bern, Inselspital, Inst Pathol, CH-3012 Bern, Switzerland

[3] Univ Dusseldorf, Klin Endokrinol Diabetol & Rheumatol, D-4000 Dusseldorf, Germany

[4] Univ Dusseldorf, Klin Allgemein Visceral & Kinderchirurg, D-4000 Dusseldorf, Germany

[5] Triemli Hosp, Inst Pathol, Zurich, Switzerland

[6] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, Konsultat Zentrum Pankreas & Neuroendokrin Tumore, D-8000 Munich, Germany

来源：

VISZERALMEDIZIN | 2010年 / 26卷 / 04期

关键词：

Gastrointestinal; Pancreas; Neuroendocrine tumor; Expression array; Comparative genomic hybridization; LOH; Loss of heterozygosity; Mutation analysis; PANCREATIC ENDOCRINE TUMORS; BETA-CATENIN PROTEIN; SUPPRESSOR GENE; MEN1; GENE; MUTATIONS; EXPRESSION; PATHOGENESIS; RAS; PROGRESSION; IMBALANCES;

D O I：

10.1159/000322151

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Gastroenteropancreatic Neuroendocrine Tumors: Molecular Genetic Features Neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET) are defined by their expression of specific endocrine marker proteins and their capacity to synthesize, store, and secrete peptide hormones and/or biogenic amines. More than 50 tumor entities can be differentiated. They can occur sporadically or can be associated with a hereditary background. The high biological and clinical variability of NET can also be shown on the level of DNA and mRNA. Recent studies show: 1. NET differ genetically from the common non-neuroendocrine carcinomas of the digestive tract. 2. The clinico-pathological heterogeneity of GEP-NET is also obvious at the genetic level. 3. Among pancreatic NET, insulinomas differ clearly in their genetic changes from non-insulinomas. 4. Tumor progression of pancreatic NET is associated with an increase in genetic changes. 5. Pancreatic NET differ genetically from gastrointestinal NET. 6. Sporadic GEP-NET differ genetically from hereditary GEP-NET.

引用

页码：283 / 288

页数：6

共 49 条

[1] Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas [J].

Anlauf, M ;

Perren, A ;

Meyer, CL ;

Schmid, S ;

Saremaslani, P ;

Kruse, ML ;

Weihe, E ;

Komminoth, P ;

Heitz, PU ;

Klöppel, G .

GASTROENTEROLOGY, 2005, 128 (05) :1187-1198

[2] Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions [J].

Anlauf, M. ;

Perren, A. ;

Henopp, T. ;

Rudolph, T. ;

Garbrecht, N. ;

Schmitt, A. ;

Raffel, A. ;

Gimm, O. ;

Weihe, E. ;

Knoefel, W. T. ;

Dralle, H. ;

Heitz, Ph U. ;

Komminoth, P. ;

Kloeppel, G. .

GUT, 2007, 56 (05) :637-644

[3] Hereditary neuroendocrine tumors of the gastroenteropancreatic system [J].

Anlauf, Martin ;

Garbrecht, Nele ;

Bauersfeld, Juliane ;

Schmitt, Anja ;

Henopp, Tobias ;

Komminoth, Paul ;

Heitz, Philipp U. ;

Perren, Aurel ;

Kloeppel, Guenter .

VIRCHOWS ARCHIV, 2007, 451 :S29-S38

[4] Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system [J].

Arnold, Christian N. ;

Sosnowski, Andrea ;

Schmitt-Graeff, Annette ;

Arnold, Rudolf ;

Blum, Hubert E. .

INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (10) :2157-2164

[5] Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression [J].

Barghom, A ;

Komminoth, P ;

Bachmann, D ;

Rütimann, K ;

Saremaslani, P ;

Muletta-Feurer, S ;

Perren, A ;

Roth, J ;

Heitz, PU ;

Speel, EJM .

JOURNAL OF PATHOLOGY, 2001, 194 (04) :451-458

[6] Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors [J].

Barghorn, A ;

Speel, EJM ;

Farspour, B ;

Saremaslani, P ;

Schmid, S ;

Perren, A ;

Roth, J ;

Heitz, PU ;

Komminoth, P .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1903-1911

[7] Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets [J].

Capurso, G. ;

Lattimore, S. ;

Crnogorac-Jurcevic, T. ;

Panzuto, F. ;

Milione, M. ;

Bhakta, V. ;

Campanini, N. ;

Swift, S. M. ;

Bord, C. ;

Delle Fave, G. ;

Lemoine, N. R. .

[8] A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications [J].

Chung, DC ;

Smith, AP ;

Louis, DN ;

GraemeCook, F ;

Warshaw, AL ;

Arnold, A .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) :404-410

[9] Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors [J].

Couvelard, Anne ;

Hu, Jiangting ;

Steers, Graham ;

O'Toole, Dermot ;

Sauvanet, Alain ;

Belghiti, Jacques ;

Bedossa, Pierre ;

Gatter, Kevin ;

Ruszniewski, Philippe ;

Pezzella, Francesco .

GASTROENTEROLOGY, 2006, 131 (05) :1597-1610

[10]

Cupisti K, 2000, EUR J CLIN INVEST, V30, P325

← 1 2 3 4 5 →